Rigel Pharmaceuticals Stock Performance
| RIGL Stock | USD 20.20 0.17 0.83% |
On a scale of 0 to 100, Rigel Pharmaceuticals holds a performance score of 7. The company holds a Beta of 2.01, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rigel Pharmaceuticals will likely underperform. Please check Rigel Pharmaceuticals' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Rigel Pharmaceuticals' historical price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Rigel Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Rigel Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.83) | Five Day Return (0.93) | Year To Date Return 16.63 | Ten Year Return (38.04) | All Time Return (96.84) |
Last Split Factor 1:10 | Last Split Date 2024-06-27 |
1 | Acquisition by Raul Rodriguez of 400000 shares of Rigel Pharmaceuticals subject to Rule 16b-3 | 12/27/2024 |
2 | Disposition of 45000 shares by Raul Rodriguez of Rigel Pharmaceuticals at 21.4 subject to Rule 16b-3 | 01/24/2025 |
3 | Acquisition by Furey Raymond J. of 14788 shares of Rigel Pharmaceuticals at 22.49 subject to Rule 16b-3 | 01/29/2025 |
4 | Disposition of 1448 shares by Furey Raymond J. of Rigel Pharmaceuticals at 20.921 subject to Rule 16b-3 | 02/04/2025 |
5 | Rigel Pharmaceuticals, Inc. CFO Dean L. Schorno Sells 2,036 Shares | 02/07/2025 |
6 | Acquisition by Ali-jackson Kamil of 25000 shares of Rigel Pharmaceuticals subject to Rule 16b-3 | 02/19/2025 |
7 | Disposition of 2036 shares by Schorno Dean L of Rigel Pharmaceuticals at 20.921 subject to Rule 16b-3 | 02/26/2025 |
8 | Rigel Pharmaceuticals Inc Q4 2024 Everything You Need To Know Ahead Of Earnings | 03/03/2025 |
9 | Rigel Pharmaceuticals GAAP EPS of 0.80 beats by 0.18, revenue of 57.6M in-line | 03/04/2025 |
10 | Rigel Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Record Revenue and Strategic ... | 03/05/2025 |
11 | Rigel Pharmaceuticals Full Year 2024 Earnings EPS Beats Expectations | 03/06/2025 |
12 | Acquisition by Kotzin Brian L. of 25000 shares of Rigel Pharmaceuticals subject to Rule 16b-3 | 03/07/2025 |
13 | Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors | 03/10/2025 |
14 | Rigel Pharmaceuticals SWOT analysis pipeline potential drives stock outlook - Investing.com India | 03/13/2025 |
15 | Acquisition by David Santos of 50000 shares of Rigel Pharmaceuticals subject to Rule 16b-3 | 03/14/2025 |
16 | Acquisition by Furey Raymond J. of 7850 shares of Rigel Pharmaceuticals at 12.7 subject to Rule 16b-3 | 03/17/2025 |
| Begin Period Cash Flow | 32.8 M |
Rigel |
Rigel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,644 in Rigel Pharmaceuticals on December 24, 2024 and sell it today you would earn a total of 376.00 from holding Rigel Pharmaceuticals or generate 22.87% return on investment over 90 days. Rigel Pharmaceuticals is currently generating 0.4376% in daily expected returns and assumes 4.4156% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Rigel, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rigel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rigel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rigel Pharmaceuticals, and traders can use it to determine the average amount a Rigel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0991
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RIGL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.42 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Rigel Pharmaceuticals is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rigel Pharmaceuticals by adding it to a well-diversified portfolio.
Rigel Pharmaceuticals Fundamentals Growth
Rigel Stock prices reflect investors' perceptions of the future prospects and financial health of Rigel Pharmaceuticals, and Rigel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rigel Stock performance.
| Return On Equity | -6.99 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 343.48 M | ||||
| Shares Outstanding | 17.86 M | ||||
| Price To Earning | (5.63) X | ||||
| Price To Book | 109.74 X | ||||
| Price To Sales | 2.01 X | ||||
| Revenue | 179.28 M | ||||
| Gross Profit | 137.25 M | ||||
| EBITDA | 28.51 M | ||||
| Net Income | 17.48 M | ||||
| Cash And Equivalents | 81.64 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 59.97 M | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | 31.47 M | ||||
| Earnings Per Share | 0.99 X | ||||
| Market Capitalization | 360.83 M | ||||
| Total Asset | 163.98 M | ||||
| Retained Earnings | (1.39 B) | ||||
| Working Capital | 71.8 M | ||||
| Current Asset | 129.02 M | ||||
| Current Liabilities | 33.8 M | ||||
About Rigel Pharmaceuticals Performance
By examining Rigel Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Rigel Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Rigel Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 117.48 | 111.61 | |
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.24 | 0.25 | |
| Return On Assets | 0.11 | 0.11 | |
| Return On Equity | 5.32 | 5.58 |
Things to note about Rigel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Rigel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rigel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rigel Pharmaceuticals had very high historical volatility over the last 90 days | |
| Rigel Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| About 69.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Furey Raymond J. of 7850 shares of Rigel Pharmaceuticals at 12.7 subject to Rule 16b-3 |
- Analyzing Rigel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rigel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Rigel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rigel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rigel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rigel Pharmaceuticals' stock. These opinions can provide insight into Rigel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 17.867 | Earnings Share 0.99 | Revenue Per Share | Quarterly Revenue Growth 0.609 | Return On Assets |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.